EN DE
Watch Lunit Inc. for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Lunit Inc. (328130) fair value: what the stock is really worth

As of Nov 17, 2026: fair value (intrinsic value) of Lunit Inc. stock KRW 12,384, price KRW 15,820, that is 21.7% below the price, quality 26 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare KR

LI Lunit Inc. logo Thin data Nov 10, 2026

Lunit Inc.

328130 · KQ

Expensive (fair value 22% below the price), weak company and falling price: meets none of the 3 rules.

Get notified free when this changes
Low debt 
Revenue last quarter +22% vs. a year ago. 
Expensive Growth (revenue 5y +125.4 %/yr in KRW) 
Fair value 12,384 KRW · Overvalued 
Quality 26/100 
Falling price (downtrend) 
Loss-making · -60.7% net margin (TTM) 
Negative free cash flow 
Trails peers (2/9) 
Narrow moat 6/100 · thin data
Thin data 
Estimate
Watch Lunit Inc. for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

56,074 KRW 4,252 KRW Fair Value 12,384 KRW Jul 2022 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

52‑month range 4,252 KRW – 56,074 KRW · fair‑value band 9,288 KRW – 15,480 KRW · the 15,820 KRW price screens above the 12,384 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow Lunit in your weekly email

Every Wednesday you see whether Lunit is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Lunit Inc. provides AI-powered software and solutions for cancer diagnostics and therapeutics in South Korea. It offers AI solution for chest X-ray and mammography, as well as AI solution for digital breast tomosynthesis, and AI-powered biomarker for immune phenotyping and PD-L1 biomarker analyzer.

Show moreShow less

The company has a strategic collaboration with AstraZeneca for the development of Lunit SCOPE Genotype Predictor, an AI-powered tool capable of analyzing H&E slide images to predict the likelihood of the tumor harboring NSCLC driver mutations, such as Epidermal Growth Factor Receptor mutations; with Agilent Technologies Inc. to create advanced solutions that meet the demand of novel and complex biomarker assays in drug development; and with Daiichi Sankyo Company, Limited to accelerate biomarker discovery and translational research.

Lunit Inc. was founded in 2013 and is based in Seoul, South Korea.

Stock analysis

Lunit Inc. (328130) currently trades at 15,820 KRW, while our estimate is 12,384 KRW, 22% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: 9,288 KRW (bear) to 15,480 KRW (bull), the price of 15,820 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 26/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Lunit Inc. reported revenue of 83.1B KRW in FY2025 versus 6.6B KRW in FY2021, a compound +88.1%/yr. Reported net income was −47.4B KRW in FY2025.

Key figures

Market cap 1.1T KRW (≈ $841M) Small · P/S ratio 12.1 · EPS (TTM) −747.92 KRW · Net margin −60.7% · Return on equity −23.5% · Return on assets (EBIT) −30.9% (5-year average) · Operating margin −70.4% · Revenue (TTM) 91.8B KRW.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 6 out of 100 (low confidence).

What moves the price

The share trades about 31% below its 52-week high and 93% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −19% fair-value upside, at −22%, 328130 screens richer than that median.

Fair Value

Bear 9,288 KRW Fair Value 12,384 KRW Bull 15,480 KRW
Price 15,820 KRW · Downside -21.7%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 26/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 10
How much profit the company makes from its sales and capital
Quality Growth 91
Are margins and returns getting better?
Cashflow 15
Do the profits arrive as real cash?
Financial strength 32
Debt, balance sheet and risk of trouble
Investment 16
Does it invest with discipline instead of growing at any price?
Low Volatility 23
How calm the share price moves, does not count
Price momentum 41
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 31
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 44/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+53.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+81.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+125.4%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+173.5%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−1,465.0% (2020) → −100.0% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

328130 screens overvalued: fair value 22% below the price. Compare with Veeva Systems Inc →

Compare Lunit Inc. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Health Information Services · 140 stocks

Beats the industry median on 1/7 measures
Overall it trails its industry peers.
Valuation
Quality Score 26 · Bottom 25%
Fair Value upside −21.7% · Below median
Profitability
Return on assets −12.8% · Below median
Net margin (12 months) −60.7% · Bottom 25%
Operating margin (12 months) −70.4% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 22.0% · Above median

Valuation Multiplesvs Health Information Services median · lower = cheaper

P/B 8.18× · book value is mostly intangible assets ⓘGoodwill and other intangible assets (such as prices paid for past acquisitions, brands, licences or film and series rights) are larger than the equity. So we do not rank this P/B against the peer group.
P/S (12 months) 12.25× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)4 · sector 15
FUTURE (revenue growth)100 · sector 46
PAST (return on equity)0 · sector 3
HEALTH (low debt)100 · sector 98
DIVIDEND (yield)0 · sector 43

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Health Information Services stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Doximity, Inc DOCS $32.77 $36.67 +12% vs 328130
Veeva Systems Inc VEEV $299.28 $329.21 +10% vs 328130
HealthEquity, Inc HQY $104.58 $115.04 +10% vs 328130
Waystar Holding WAY $28.11 $29.10 +4% vs 328130
Tempus AI, Inc TEM $64.76 $52.58 −19% vs 328130
HeartFlow, Inc HTFL $46.86 $30.50 −35% vs 328130
Hinge Health, Inc HNGE $121.29 $51.25 −58% vs 328130
Pro Medicus Limited PME A$201.65 A$82.80 −59% vs 328130
BrightSpring Health Services, Inc BTSG $71.37 $25.72 −64% vs 328130
XtalPi Holdings 2228 HK$5.32 HK$1.53 −71% vs 328130

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Lunit Inc.: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Lunit Inc. Fair Value". https://www.fairvalue-calculator.com/stock/328130

Frequently asked questions

Is Lunit Inc. (328130) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is 12,384 KRW versus a price of 15,820 KRW, about 22% lower (overvalued).
What is the fair value of 328130?
Our estimate for Lunit Inc. is 12,384 KRW (as of Nov 10, 2026), built from audited fundamentals. The current price: 15,820 KRW.
What is the quality score of 328130?
Lunit Inc. has a Quality Score of 26/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Lunit Inc. (328130)?
Our calculated price target is the estimate of 12,384 KRW (as of Nov 10, 2026). Cautious scenario 9,288 KRW, optimistic scenario 15,480 KRW. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Lunit Inc. stock forecast for 2026?
Our estimate puts fair value at 12,384 KRW, about 22% lower versus a price of 15,820 KRW (overvalued). Cautious scenario 9,288 KRW, optimistic scenario 15,480 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Lunit Inc. (328130)?
Lunit Inc. reported trailing-twelve-month revenue of about 91.8B KRW (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of Lunit Inc. (328130)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Lunit Inc. it is 12,384 KRW per share (as of Nov 10, 2026), against a price of 15,820 KRW.
Is Lunit Inc. stock overvalued or undervalued in 2026?
As of Nov 10, 2026, 328130 trades above its calculated fair value: price 15,820 KRW, fair value 12,384 KRW, a gap of about −22% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 328130?
No. The price is what the market pays today (15,820 KRW); the fair value is what the company's own numbers justify (12,384 KRW). For Lunit Inc. the two are 3,436 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Lunit Inc. worth?
The market values Lunit Inc. at about 1.1T KRW (market capitalisation, as of Nov 10, 2026). Per share that is 15,820 KRW; our models calculate a fair value of 12,384 KRW per share.
What do the bullish and bearish scenarios say about 328130?
Our models span a range for Lunit Inc.: cautious scenario 9,288 KRW, base 12,384 KRW, optimistic 15,480 KRW per share (as of Nov 10, 2026, price 15,820 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Lunit Inc. (328130)?
Balance-sheet figures for Lunit Inc. (as of Nov 10, 2026): return on equity −23.5%. They feed the Quality Score of 26/100, which measures business quality independently of the share price.
How far is 328130 from its 52-week high?
Lunit Inc. trades at 15,820 KRW, about 31% below its 52-week high of 22,934 KRW and 93% above the low of 8,210 KRW (as of Nov 17, 2026). Distance from the high says nothing about value: that is what the fair value of 12,384 KRW is for.
Which stocks are comparable to Lunit Inc.?
From the same area (Healthcare) we also value Veeva Systems Inc, Pro Medicus Limited, BrightSpring Health Services, Inc, Tempus AI, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Lunit Inc. stock attractive at the current price?
The data as of Nov 10, 2026: price 15,820 KRW, calculated fair value 12,384 KRW (−22%), Quality Score 26/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 13.6% above its aggregate fair value. Lunit Inc. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Lunit Inc. (328130)?
The closing price on Nov 17, 2026 was 15,820 KRW. Our estimate is 12,384 KRW, about 22% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Lunit Inc. right now?
The price sits above even our optimistic bull case (15,480 KRW). The favourable scenario is already priced in. Weak quality (26/100) and above fair value at the same time, the margin of safety is missing on both counts. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Lunit Inc.

How large is the market capitalisation of Lunit Inc. (328130)?
The market capitalisation of Lunit Inc. is 1.1T KRW (≈ $841M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Lunit Inc. (328130)?
The price-to-sales ratio of Lunit Inc. is 12.1 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Lunit Inc. (328130)?
Earnings per share at Lunit Inc. are −747.92 KRW. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Lunit Inc. (328130)?
The net margin of Lunit Inc. is −60.7% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Lunit Inc. (328130)?
The return on equity (ROE) of Lunit Inc. is −23.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Lunit Inc. (328130)?
On an EBIT basis the return on assets of Lunit Inc. is −30.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Lunit Inc. (328130)?
The operating margin of Lunit Inc. is −70.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Lunit Inc. (328130)?
Revenue at Lunit Inc. is growing 22.0% versus a year earlier (3y avg +81.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Lunit Inc. (328130) generate?
The free cash flow of Lunit Inc. is −64.8B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Lunit Inc. (328130) carry?
The net debt of Lunit Inc. is 79.3B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Lunit Inc. in the live analysis

One click puts Lunit Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.